Journal of AIDS & Clinical Research

L. Finkielsztejn

Publications

• Research Article
  Tolerance and Durability of Abacavir/Lamivudine (Abc/3tc) Containing Regimens: Results from a large French Prospective Cohort
  Author(s): L. Cuzin, C. Allavena, L. Finkielsztejn, H. Melliez, P. Pugliese, I. Poizot-Martin, C. Duvivier, L. Levy-Bachelot and S. AbelL. Cuzin, C. Allavena, L. Finkielsztejn, H. Melliez, P. Pugliese, I. Poizot-Martin, C. Duvivier, L. Levy-Bachelot and S. Abel
  
  Background: Abacavir is considered as a potent and well tolerated drug but recent controversial data have raised questions concerning cardiovascular tolerability and virological efficacy in antiretroviral initial regimen with abacavir/lamivudine (ABC/3TC). Methods: Patients were selected from the Dat’AIDS french prospective cohort if they were prescribed a regimen containing ABC/3TC free or fixed dose combination for the first time between 01/01/2004 and 31/12/2007 before HLA screening recommendation or routine usage. All causes of treatment discontinuation were recorded, as well as immuno-virological and clinical data during follow-up. Results: Among the 1704 patients included in the study (male 69%, mean age 43 years) 407 (24%) were antiretroviral naïve, 696 (41%) had viral load (VL) below detection on ARV treatment (switch), and 601 (35%) were on treatment with detectabl.. Read More»
  DOI: 10.4172/2155-6113.S1-019

  Abstract PDF